Glaukos Co. (NYSE:GKOS) Stake Raised by Federated Hermes Inc.

Federated Hermes Inc. increased its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 68.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,862 shares of the medical instruments supplier's stock after buying an additional 8,863 shares during the period. Federated Hermes Inc.'s holdings in Glaukos were worth $2,587,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in GKOS. Dimensional Fund Advisors LP grew its position in shares of Glaukos by 3.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier's stock worth $73,412,000 after buying an additional 31,213 shares in the last quarter. Norges Bank purchased a new stake in shares of Glaukos in the 4th quarter valued at approximately $28,807,000. Nomura Holdings Inc. raised its holdings in shares of Glaukos by 3.2% in the 4th quarter. Nomura Holdings Inc. now owns 232,034 shares of the medical instruments supplier's stock valued at $18,444,000 after purchasing an additional 7,146 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Glaukos in the 2nd quarter valued at $6,832,000. Finally, Natixis purchased a new stake in shares of Glaukos during the 1st quarter worth $614,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GKOS. BTIG Research upped their price objective on Glaukos from $131.00 to $139.00 and gave the stock a "buy" rating in a research report on Wednesday, August 28th. Morgan Stanley upped their price target on Glaukos from $100.00 to $120.00 and gave the company an "equal weight" rating in a report on Monday, July 15th. StockNews.com cut shares of Glaukos from a "hold" rating to a "sell" rating in a report on Friday, August 30th. Piper Sandler upped their target price on shares of Glaukos from $110.00 to $140.00 and gave the company an "overweight" rating in a report on Thursday, August 1st. Finally, Stifel Nicolaus lifted their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $129.82.

Glaukos Price Performance

Shares of GKOS stock traded down $0.77 during midday trading on Friday, reaching $129.30. 330,124 shares of the company traded hands, compared to its average volume of 583,966. The firm's 50 day simple moving average is $124.75 and its two-hundred day simple moving average is $111.08. The firm has a market cap of $6.51 billion, a PE ratio of -45.18 and a beta of 1.03. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67. Glaukos Co. has a 1-year low of $59.22 and a 1-year high of $136.60.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, meeting the consensus estimate of ($0.52). Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. During the same quarter in the prior year, the company earned ($0.55) earnings per share. Glaukos's revenue was up 19.0% compared to the same quarter last year. On average, equities research analysts expect that Glaukos Co. will post -2.18 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of Glaukos stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the sale, the director now directly owns 30,119 shares in the company, valued at approximately $3,614,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Aimee S. Weisner sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the sale, the director now directly owns 30,119 shares of the company's stock, valued at approximately $3,614,280. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Marc Stapley sold 6,250 shares of the business's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $125.93, for a total transaction of $787,062.50. Following the sale, the director now owns 34,076 shares of the company's stock, valued at approximately $4,291,190.68. The disclosure for this sale can be found here. Insiders sold a total of 41,500 shares of company stock valued at $5,099,000 in the last ninety days. Insiders own 6.40% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.